Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O00287
UPID:
RFXAP_HUMAN
Alternative names:
RFX DNA-binding complex 36 kDa subunit
Alternative UPACC:
O00287; B2R9T8; Q5VZM6; Q8TC40
Background:
The Regulatory factor X-associated protein, also known as RFX DNA-binding complex 36 kDa subunit, plays a crucial role in the immune system. It is a key component of the RFX complex, which is essential for the binding to the X-box of MHC II promoters, a process vital for the proper expression of MHC II genes.
Therapeutic significance:
Linked to Bare lymphocyte syndrome 2, a severe immunodeficiency disease, this protein's dysfunction leads to a significant decrease in MHC II expression, resulting in a compromised immune response. Understanding the role of Regulatory factor X-associated protein could open doors to potential therapeutic strategies for enhancing immune function.